Related Experiment Videos
New therapeutic options for acromegaly.
M Arosio1, C L Ronchi, P Epaminonda
1Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, Milan, Italy. maura.arosio@unimi.it
Minerva Endocrinologica
|March 15, 2005
Summary
Acromegaly, caused by excess growth hormone (GH) and insulin-like growth factor-I (IGF-I), significantly increases mortality. Effective treatment aims to normalize GH and IGF-I levels, improving life expectancy.
Area of Science:
- Endocrinology
- Oncology
- Metabolic Diseases
Background:
- Acromegaly is a chronic disorder resulting from excess growth hormone (GH) and insulin-like growth factor-I (IGF-I).
- This condition, typically caused by a pituitary somatotroph adenoma, leads to significant morbidity and a 2-3 fold increase in mortality.
- Associated comorbidities include cardiovascular disease, diabetes mellitus, hypertension, and sleep apnea.
Purpose of the Study:
- To review current therapeutic options for acromegaly.
- To discuss the importance of normalizing GH and IGF-I levels for patient outcomes.
- To provide an overview of novel pharmacological agents and their potential role in treatment.
Main Methods:
- Literature review of existing therapeutic strategies for acromegaly.
- Analysis of the impact of GH and IGF-I excess on patient mortality and morbidity.
- Summary of pharmacological advancements, including new drugs and formulations.
Main Results:
- Normalization of serum IGF-I and GH levels is crucial for improving life expectancy.
- Current treatment modalities include surgery, radiotherapy, and pharmacotherapy.
- New drugs effectively inhibit GH secretion or action, offering alternatives or adjuncts to traditional treatments.
Conclusions:
- Aggressive and often multi-modality treatment is necessary to manage acromegaly effectively.
- Recent pharmacological innovations provide promising options for controlling GH and IGF-I excess.
- Further research into innovative drugs is ongoing to improve acromegaly management.